Barely Significant
← all excerpts

Intranasal administration of a synthetic TLR4 agonist INI-2004 significantly reduces allergy symptoms following therapeutic administration in a murine model of allergic sensitization.

Front Immunol · 2024 · PMC11300337 · PMID 39108263

Europe PMCDOI
1
hedged sentence
0.0010
closest p · 0.0× alpha
0.0010
boldest claim

The sentences

highly significantp ≤ 0.001actually significant
Therapeutic treatment with INI-2004 led to a highly significant (p ≤ 0.001) reduction in lung eosinophil influx across both INI-2004 doses and treatment cohorts ( Figure 3 ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.